Market Newsdesk

WISeKey’s Subsidiary, WISe.ART Launches a Marketing Campaign Aiming to Enlist Galleries, Museums, and Artists on its MarketPlace

Calling All Artists: Dive into the Future of Art with WISe.ART!

Geneva – October 13, 2023 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced that is subsidiary WISe.ART is launching a marketing campaign aiming to enlist galleries, museums, and artists on its NFT MarketPlace. Interested parties can join the platform vis WISe.ART.

How it works

• The platform offers all artists and curators/agents the ability to join and submit applications. Onboarding is free.
• WISe.ART vetting committee to evaluate each submission and connect with each artist personally.
• WISe.ART welcomes tokenisation of collectibles such as jewellery, design, real estate gems and precious metals.
• Artists to collect 80% of the sales price when their creations are sold and minted.

Why choose WISe.ART

• Dynamic Marketplace: Join a growing marketplace where arts and technology come alive, connecting everyone, from curators to enthusiasts.
• Beyond Just Digital: Whether you’re a traditional artist or a digital visionary, your art deserves the best. WISe.ART ensures each digital asset is authenticated and uniquely linked to its physical counterpart.
• Security & Authenticity: Peace of mind is priceless. WISe.ART platform guarantees proof of ownership, provenance, and clear contracts for future use and monetization.
• Unique Tokenisation Capabilities: Stand out with our distinctive designs, white labelling, and options tailored for curators and multipliers.
• Mint & Trade on Hedera: Experience seamless minting and trading within the WISeKey ecosystem, built atop the robust Hedera platform.
• Anonymity with Integrity: WISe.ART respects your privacy, while allowing you to remain anonymous, our KYC processes ensure a transparent and untainted marketplace for all.
• Effortless Access: With WISeID, dive into the world of art on both web and mobile platforms, fortified by strong authentication.

The future of art is here, and it’s technological, authentic, and global. Embrace the change and become a part of the art evolution with WISe.ART!

Turn your passion into opportunities. Join us now! See our artists at https://platform.wise.art/artists-index/

About WISeKey: WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, and (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions.

About WISe.ART: WISe.ART platform leverages WISeKey’s strong cybersecurity expertise, digital identity technology, and the power of blockchain to offer a unique marketplace for NFTs, connecting artists, buyers, and collectors, while ensuring the provenance and authenticity of digital artworks.

Press and investor contacts:

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

• CUNY’s report makes no findings of data manipulation.
• The “
  
  egregious misconduct
  
  ” cited in the report relates to internal record-keeping failures at CUNY.
• CUNY’s report finds that internal record-keeping failures “
  
  prevented us [CUNY] from making an objective assessment
  
  ” of research misconduct.
• Leak of CUNY report preceded by massive increase in short selling.

AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY). This report was leaked to the press. The leak of the CUNY report was preceded by a 40% increase in short selling activity in the stock of Cassava Sciences.

Beginning August 2021, short sellers executed a brutal, widely publicized “short-and-distort” campaign against Cassava Sciences. The short-sellers alleged that Cassava Sciences and its academic researcher at CUNY had engaged in data manipulation and other forms of research misconduct. In response to these allegations, CUNY initiated an internal investigation in Fall 2021. In 2022, Cassava Sciences filed a lawsuit against certain individuals who participated in the short-and-distort campaign, identifying over 1,000 false and defamatory statements.

On October 12, 2023, Science reported that it had obtained a copy of CUNY’s report from “a person who requested anonymity because they are not authorized to share it.” The Science article quotes a person paid by a lawyer for certain short-sellers, but does not indicate what role, if any, short-sellers had in the leak. According to Science, CUNY completed its investigation in May 2023. The short interest in Cassava Sciences’ stock jumped 40%, to over 14 million shares, between June 30, 2023, and September 29, 2023, according to NASDAQ.

CUNY’s report makes no findings of data manipulation. Rather, the “egregious misconduct” cited in the report relates exclusively to internal record-keeping failures at CUNY. The report also finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of the allegations of research misconduct.

“We remain confident in the underlying science for simufilam, our lead drug candidate,” said Remi Barbier, President & CEO. “We intend to continue to translate our passion for science into a novel drug for people living with Alzheimer’s disease. Our Phase 3 clinical program continues.”

Cassava Sciences played no role in CUNY’s investigation. The university turned down all requests for information and offers of assistance from Cassava. Because CUNY did not interview any employee of Cassava Sciences, the university has no legitimate basis on which to make accusations against the Company or its employees.

CUNY has not responded to an inquiry Cassava Sciences made yesterday regarding the authenticity of the leaked report.

Importantly, Cassava Sciences does not rely exclusively on research at CUNY. The science underlying simufilam, Cassava Sciences’ lead drug candidate, is supported by the work of scientists at academic institutions that have no connection to CUNY, including:

• In September 2023, Cassava Sciences announced the publication of new research that confirms the biological activity of simufilam. Researchers at the Cochin Institute (Paris, France) used a highly precise cell-based assay to show that simufilam interrupts amyloid binding to the α7 nicotinic acetylcholine receptor. Cassava Sciences believes this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease. The research appears in a special issue of International Journal of Molecular Sciences, a peer-reviewed scientific publication, and is currently available on-line at: https://www.mdpi.com/1422-0067/24/18/13927
• In May 2023, Cassava Sciences announced the publication of new data that highlights the biological activity of simufilam on Filamin A. Researchers at the University of Milan (Italy) showed a functional interaction between simufilam, filamin A (FLNA) and somatostatin receptors. Specifically, the researchers showed that simufilam treatment significantly reduced levels of phosphorylation at a site on FLNA in human pituitary tumor cells. The research was presented at the 25^thEuropean Congress of Endocrinology and is currently available on-line at: https://www.endocrine-abstracts.org/ea/0090/ea0090oc7.5

• In February 2020, Cassava Sciences announced that filamin A inhibition by simufilam reduced seizure activity in a mouse model of epilepsy. The data was generated by researchers at Yale University, was published in Science Translational Medicine and is currently available on-line at: https://pubmed.ncbi.nlm.nih.gov/32075941/

Other independent researchers have shown a role for filamin A in neurodegeneration.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established in humans.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Eric Schoen, Chief Financial Officer
(512) 501-2450
[email protected]

Cautionary Note Regarding Forward-Looking Statements:


This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the continuation of our Phase 3 clinical program; results of research relating to simufilam and to the mechanism of action underlying simufilam;
the treatment of patients with Alzheimer’s disease dementia;
comments made by our employees regarding the purported CUNY report, our science or simufilam and the treatment of Alzheimer’s disease; the continued development of simufilam; and potential benefits, if any, of our product candidates. These statements may be identified by words such as “may,” “anticipate,” “believe,” “could,” “expect,” “look forward,” “would”, “forecast,” “intend,” “plan,” “possible,” “potential,” and other words, phrases, and terms of similar meaning.

Simufilam is our investigational product candidate. Its safety, efficacy or science has not reviewed or approved by any regulatory authority in any jurisdiction and its desirable clinical attributes, if any, have not been established in patients.

Drug development involves a high degree of risk, and only a small number of research and development programs result in regulatory approval and commercialization of a product.
Clinical results from our prior studies may not be indicative of results of future or larger scale clinical trials and do not ensure regulatory approval.
You should not place undue reliance on these statements or any scientific data we present or publish.

Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of inflation on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at

www.sec.gov

.

ATHENS, Greece, Oct. 12, 2023 (GLOBE NEWSWIRE) — TEN Ltd. (“TEN”) (NYSE: TNP) (the “Company”), celebrated its 30th year as a publicly listed company. TEN was listed on the Oslo Stock Exchange in 1993 and transferred its listing to the New York Stock Exchange in March 2002.

On October 10, 2023, Dr. Nikolaos P. Tsakos, Founder, CEO and his family hosted a memorable event in New York City along with members of the executive team. The event was attended by prominent financial journalist and anchor, Mrs. Nicole Petalides from Schwab Network, who delivered introductory remarks in the presence of Mr. Chris Taylor, Vice President and Global Head of Listings & Services at NYSE, Mr. Stefan Jekel, Head of International Listings at NYSE and other distinguished guests from the international shipping industry, banking and investment communities to mark this monumental occasion.

The Company proudly celebrated its journey which began 30 years ago with a fleet of four tankers to becoming one of the largest independent transporters of energy in the world owning a versatile fleet of 68 modern crude and product tankers, shuttle tankers and liquefied natural gas (“LNG”) vessels. TEN Ltd. is the energy transporter of choice for major oil companies and other blue chip global energy concerns.  

TEN’s focus on fleet modernity, operational excellence and balanced fleet employment has enabled the company to produce strong results throughout the market cycles. Over its 20-year presence on NYSE, TEN Ltd. has generated net income in excess of $2.5 billion and has made uninterrupted payments of common and preferred dividends in excess of $750 million, regardless of market cyclicality.

TEN Ltd. was among the first tanker companies to embrace the double hull vessel concept in the design and today remains committed to fleet modernization and green energy transition. TEN Ltd. has implemented a $6.0 billion newbuilding program on fleet expansion and renewal underpinning its prudent sustainable growth strategy aiming at reducing the Company’s environmental footprint.

On September 25, 2023, TEN Ltd. took delivery of an LNG powered Aframax tanker, Njord DF, the first in a series of four high-spec eco designed vessels built against long-term employment to a major European state-owned oil concern. The introduction of this vessel kickstarts the delivery of the Company’s existing green growth program with now nine remaining vessels which are expected to be gradually introduced to TEN’s fleet over the next ten quarters.

As of today, TEN Ltd. has secured over $2.5 billion in fleet revenue backlog.

Dr. Nikolaos P. Tsakos, Founder and CEO of the Company commented:

“This exceptional moment represents a significant milestone in our history as a publicly traded company that not only celebrates its achievements but more importantly, it propels us to look ahead into our next chapter and continue to push forward to better our business and our practices. We are grateful and appreciative to all our associates for their efforts so far and remain enthusiastic as we embark on the next phase of the Company’s development for the benefit of our shareholders.

ABOUT
TSAKOS
ENERGY
NAVIGATION

TEN, founded in 1993 and celebrating this year 30 years as a public company, is one of the first and most established public shipping companies in the world. TEN’s diversified energy fleet currently consists of 68 double-hull vessels, including four dual-fuel LNG powered aframax vessels, two DP2 shuttle tankers, two scrubber-fitted suezmax vessels and two scrubber-fitted MR product tankers under construction, constituting a mix of crude tankers, product tankers and LNG carriers, totaling 8.4 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company

Tsakos Energy Navigation Ltd.
George Saroglou
COO
+30210 94 07 710
[email protected]

Investor Relations / Media

Capital Link, Inc.
Nicolas Bornozis
Markella Kara
+212 661 7566
[email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6b9376de-ac1e-40df-a3d0-6fbe72246b9e

https://www.globenewswire.com/NewsRoom/AttachmentNg/31b1c386-1e8e-4d4a-a2fa-a5ea1f8479e0

SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired PureCycle Technologies, Inc. (NASDAQ: PCT) securities between August 8, 2023 and September 13, 2023. PureCycle claims it is commercializing a patented purification recycling technology, originally developed by The Procter & Gamble Company (“P&G”), for restoring waste polypropylene into resin with near-virgin characteristics, called ultra-pure recycled resin.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: PureCycle Technologies, Inc. (PCT) Failed to Inform Investors its Ironton Facility Experienced a Power Outage

According to the complaint, in early 2023, PureCycle claimed that it was finalizing construction and commissioning at its first commercial scale recycling facility (the “Ironton Facility”). On September 13, 2023, PureCycle disclosed that its Ironton Facility experienced a full plant power outage on August 7, 2023, which required the facility to halt operations. The Company further disclosed that it replaced a seal that purportedly failed as a result of the power outage, and initiated facility restart procedures on September 11, 2023. On this news, PureCycle’s stock price fell $1.395, or 18.4%, to close at $6.18 per share on September 14, 2023, on unusually heavy trading volume.

What Now: Similarly situated shareholders may be eligible to participate in the class action against PureCycle Technologies, Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 28, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against PureCycle Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.